ACAD — ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenues: $308 million, a 17% year-over-year growth on an adjusted basis.
• DAYBUE Net Sales: $125 million, up 30% year-over-year, driven by strong uptake of the newly launched DAYBUE STIX formulation.
• NUPLAZID Net Sales: $183 million, a 10% year-over-year increase, supported by a 20% rise in new patient prescriptions.
• Operating Expenses: R&D expenses were $82 million (up from $78 million YoY), and SG&A expenses were $160 million (up from $134 million YoY).
• Cash Position: $956 million, providing financial flexibility for future initiatives.
• Revised Guidance: DAYBUE sales outlook raised to $480 million - $510 million; NUPLAZID sales guidance remains at $760 million - $790 million.

2. Strategic Updates and Business Highlights

• DAYBUE STIX: Strong early adoption, with 40% of U.S. DAYBUE patients using STIX by the end of Q2. The product is expected to drive continued growth.
• Regulatory Milestone: Positive opinion from the CHMP for DAYBUE in the EU, with plans for commercialization in Germany by Q4 2026.
• Pipeline Progress: Focus on remlifanserin for Alzheimer's disease psychosis, with Phase II results expected in September to October 2026. Fast Track designation received from the FDA.
• Expanded Field Force: Increased engagement with healthcare providers is expected to enhance NUPLAZID's market presence.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Total expected revenue of $1.24 billion to $1.3 billion.
• DAYBUE Sales Goal: Confidence in achieving $700 million in sales by 2028, with 15% of that expected from international markets.
• NUPLAZID Sales Goal: Aiming for approximately $1 billion in sales by 2028.

4. Bad News, Challenges, or Points of Concern

• R&D Spending: Guidance for R&D expenses lowered to $355 million - $380 million due to a milestone shift to 2027 and portfolio prioritization.
• Market Dynamics: Potential competition from gene therapies in the Rett syndrome space, although management believes DAYBUE will remain the standard of care.
• Enrollment Concerns: Slow enrollment in other ADP trials (e.g., Bristol's ADEPT) raises questions about the broader market's capacity for patient recruitment.

5. Notable Q&A Insights

• Patient Dynamics for DAYBUE STIX: 60% of STIX users were new patients, while 40% were returning. The company is optimistic about continued growth as they expand outreach beyond centers of excellence.
• Market Research on Gene Therapies: Management does not anticipate significant impact on DAYBUE's forecast from potential gene therapies.
• RADIANT Trial Design: The Phase II study is designed to enroll a more severe psychosis population, with expectations for a 0.4 effect size on the SAPS-H+D endpoint.
• Statistical Analysis: The RADIANT study will use MMRM for analysis, with a focus on maintaining rater consistency throughout the trial.

Overall, ACADIA Pharmaceuticals reported a strong quarter with significant growth in revenues and strategic advancements, particularly with DAYBUE and NUPLAZID. However, they face challenges in R&D spending and potential competition in the market.